3D Systems Acquires Volumetric

October 27, 2021

pH Partners Serves as the Exclusive Sell-Side Advisor to Volumetric

Houston, TX, October 27, 2021 – pH Partners, LLC, a boutique healthcare investment bank is pleased to announce that its client, Volumetric Biotechnologies Inc., a 3D tissue printing technology founded by Drs. Jordan Miller and Bagrat Grigoryan, has been acquired by 3D Systems. 3D Systems, led the translation of 3D printing into commercial manufacturing and is the leading additive manufacturer across a range of advanced applications in healthcare and industry.

Volumetric, a Houston-based biotech company has developed a 3D bioprinting platform that create biomaterials with living cells for applications in human organ replacement. The platform produces stereolithographic bio-printers and an assortment of bio-inks to produce vascularized tissues and organs hundreds of times faster than other bioprinting technologies.

Ben Perkins, Managing Director of pH Partners, stated, ”This acquisition aligns the market leader in 3D manufacturing with Volumetric, the most innovative company in bioprinting. We believe the real winners today are patients who may finally have a scalable solution to the chronic shortage of organs for transplantation.”

​To read more, visit the press release here.

About pH Partners

pH Partners, LLC, is a boutique investment banking firm delivering capital formation, strategic partnership, and merger and acquisition services to companies at the convergence of Healthcare, Technology and the Consumer. The pH Partners team consists of senior-level executives with extensive backgrounds in investment banking, life sciences, medicine and operations, and have collectively closed over $20B in strategic advisory transactions, and have raised more $5B in capital for their clients. pH Partners is headquartered in Austin, Texas with offices in Houston, Portland and New York. To learn more, visit phpartners.com.

pH Partners’ transaction leads:

Benjamin Perkins
Managing Partner

Erik Halvorsen, Ph. D
Partner

Sell-Side Advisory
Medical Device
$400M*
Undisclosed